Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) Shares Outstanding (Weighted Average) (2023 - 2026)

Beta Bionics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $44.4 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 44.67% to $44.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $44.4 million, a 44.67% increase, with the full-year FY2024 number at $6.4 million, up 20.01% from a year prior.
  • Shares Outstanding (Weighted Average) hit $44.4 million in Q1 2026 for Beta Bionics, up from $43.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for BBNX hit a ceiling of $44.4 million in Q1 2026 and a floor of $5.3 million in Q4 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $20.7 million across 4 years, with a median of $6.7 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 20.01% in 2024 and later soared 555.12% in 2025.
  • Tracing BBNX's Shares Outstanding (Weighted Average) over 4 years: stood at $5.3 million in 2023, then rose by 20.01% to $6.4 million in 2024, then skyrocketed by 585.52% to $43.6 million in 2025, then increased by 1.84% to $44.4 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BBNX at $44.4 million in Q1 2026, $43.6 million in Q3 2025, and $37.1 million in Q2 2025.